Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab

@article{Leussink2008RituximabIC,
  title={Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab},
  author={V. Leussink and H. Lehmann and G. Meyer zu H{\"o}rste and H. Hartung and O. St{\"u}ve and B. Kieseier},
  journal={Journal of Neurology},
  year={2008},
  volume={255},
  pages={1436-1438}
}
JO N 2 95 6 II trial in relapsing-remitting MS (RRMS) [6–9]. At present, the duration of the treatment effect, its effect on progression of disability, and types of adverse events associated with this drug that may occur remain elusive [10]. We report an 18-year old righthanded Caucasian male who was diagnosed with RRMS in 2001 at the age of 12 years by a neurologist in private practice. At that time, the patient experienced 3–4 relapses per year, and treatment was initiated with interferon… Expand
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report
Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?
Practical considerations on the use of rituximab in autoimmune neurological disorders
Rituximab and Multiple Sclerosis
Targeting B Cells to Modify MS, NMOSD, and MOGAD
Autoimmune disease: A role for new anti-viral therapies?
...
1
2
...

References

SHOWING 1-10 OF 14 REFERENCES
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Treatment and treatment trials in multiple sclerosis
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Multiple sclerosis: a complicated picture of autoimmunity
The Immunopathology of Multiple Sclerosis: An Overview
...
1
2
...